Does Hunger Go Away? What Happens to Appetite After Years of Dieting

The question comes up in clinic, and in patient communities, and in the back of the mind of anyone who has been managing their weight for long enough. Does this ever get easier? Does the hunger eventually settle? Is there a point — six months in, a year in, five years in — where the body stops fighting and lets the new weight be the new weight?

It would be more comfortable to tell people yes. The available longitudinal data does not support that answer for most people who have lost weight through dieting alone. The hormonal posture that emerges during sustained restriction is unusually persistent, and the longer it has been studied, the longer it appears to last. The clinical reframe — obesity as a chronic disease requiring ongoing management rather than a temporary problem to be solved — emerges directly from this evidence.

The twelve-month answer: still hungrier

Priya Sumithran's 2011 study at the University of Melbourne is the reference point for this question, for one specific reason: it followed participants long after their formal intervention had ended. Most weight-loss studies terminate at the loss phase. Sumithran's cohort was tracked to 62 weeks — more than a year after a ten-week very-low-calorie diet.

At 62 weeks, ghrelin was still elevated above baseline. Leptin, peptide YY, cholecystokinin, GIP, insulin, and amylin were still suppressed. Self-reported hunger was higher than at any earlier study timepoint. Most participants had regained some weight, but the hormonal pattern did not normalise even where it might have been expected to follow weight back upward.

The implication that drew clinical attention was the asymmetry. Weight loss had created a hormonal environment that did not reverse spontaneously over a year, regardless of whether the participant was still actively restricting. The system had registered a loss and remained in defensive posture.

The six-year answer: still adapted

The longest follow-up study on this question came from Erin Fothergill and Kevin Hall's team at the National Institute of Diabetes and Digestive and Kidney Diseases, published in Obesity in 2016. The cohort was unusual: former contestants from The Biggest Loser, who had lost an average of 58 kg through extreme caloric restriction and exercise over 30 weeks of the competition.

Six years later, the investigators measured resting metabolic rate and hormonal markers in the participants. Resting metabolic rate was, on average, 499 kcal per day below what would be predicted from their body composition — a substantial and clinically meaningful deficit that had persisted across six years of post-competition life. Leptin levels were significantly lower than expected for their body fat. The metabolic adaptation had not resolved with time.

Most contestants had regained substantial weight, but the metabolic deficit persisted in those who had regained the most as well as those who had maintained loss. The adaptation appeared to be a stable feature of the post-loss state rather than a transient response to active restriction.

Why the body holds the posture

The evolutionary framing is straightforward. For most of human history, the survival-relevant signal in caloric scarcity was not "diet ending soon" but "scarcity may continue indefinitely." A hormonal response calibrated to defend energy stores under indefinite duress would have been adaptive. The system was not designed to recognise the difference between a famine and a programme that was supposed to end at week 30.

This is a structural feature, not a defect. The same biology that makes weight regain after dieting so reliable was, in earlier environments, the biology that protected the species from periodic food shortages.

What happens at three, five, ten years

Beyond the Fothergill cohort, longer-term data thins out — long-term weight-loss follow-up is logistically difficult and expensive. The available evidence from observational studies of people who have maintained substantial weight loss (the National Weight Control Registry, in particular) suggests that maintenance requires sustained vigilance — high physical activity, consistent dietary self-monitoring, and ongoing behavioural effort — at levels that most people do not sustain indefinitely. The hormonal substrate the registrants are working against does not appear to relent.

The clinical reframe in obesity medicine over the last decade has absorbed this evidence directly. The American Medical Association classified obesity as a chronic disease in 2013, and major endocrine and obesity societies have followed. The reframe rests partly on the persistence of the adaptive response — a condition whose underlying biology does not normalise without ongoing intervention meets a reasonable definition of chronic.

The contrasting trajectory under GLP-1 medication

The STEP and SURMOUNT trial programmes have provided the first comparable long-term hunger data under pharmacological treatment. The pattern looks different from the post-restriction trajectory in several ways.

John Wilding's STEP 1 trial, published in the New England Journal of Medicine in 2021, followed participants on once-weekly semaglutide 2.4mg for 68 weeks. Appetite-related patient-reported outcomes showed substantial and sustained reductions in hunger, food cravings, and food preoccupation across the full treatment period. Unlike the post-dieting trajectory where hunger climbs over time, the on-treatment trajectory remained suppressed at the end of the study window.

The STEP 4 extension trial — also led by Thomas Wadden — was particularly informative. Participants were randomised at week 20 to either continue semaglutide or switch to placebo. The continuation group maintained their weight loss; the placebo group regained two-thirds of it within the next 48 weeks, with hunger ratings climbing back toward baseline. The hormonal pressure that drives regain was demonstrably suppressed by the medication and demonstrably re-emerged once it was withdrawn.

This is the clinical evidence that has driven the framing of GLP-1 treatment as ongoing rather than temporary. The drug controls the signal while it is being taken; the signal returns when it isn't. That pattern is consistent with chronic disease pharmacotherapy in other contexts — antihypertensives, statins, antidepressants — and inconsistent with the cure-then-stop model that dieting implicitly assumes.

What "maintenance dose" means in this context

The clinical practice that has emerged is to titrate to an effective weight-loss dose, achieve and stabilise the new weight, and then continue at a maintenance dose indefinitely. The phrasing matters: maintenance does not mean tapering off, because the hormonal posture that drives regain re-emerges within months of discontinuation in most patients.

The framing some patients find helpful is comparison with thyroid replacement after thyroidectomy: the gland is gone, the hormone has to be supplied, and the supplementation continues for life. The hormonal environment that GLP-1 medication produces is the environment in which the new weight is sustainable; outside it, the system reverts.

What this changes about the question

The original question — does hunger go away — was framed for a model of weight loss in which the difficult phase ends and a stable easier phase begins. The biology does not appear to support that model. The reasons dieting alone tends to fail in the long term are not principally about discipline running out; they are about a hormonal environment that does not normalise without ongoing intervention.

That reframing changes the implicit goal of treatment. The question is not "how long until I can stop?" but "what level of intervention can be sustained indefinitely?" For some people that is structured maintenance behaviour with high vigilance. For others — for whom the underlying biological pressure is too strong to be managed behaviourally — it is ongoing pharmacotherapy. Neither is failure. Both are reasonable responses to the same underlying mechanism.

Key takeaways

• Sumithran's 2011 study found post-diet hormonal shifts (elevated ghrelin, suppressed satiety hormones) persisting at 62 weeks, with self-reported hunger highest at that endpoint.
• Fothergill's 2016 study of former Biggest Loser contestants found resting metabolic rates 499 kcal/day below predicted six years after the competition — the adaptation had not resolved.
• The National Weight Control Registry suggests long-term maintenance is possible but requires sustained high-effort behavioural strategies, consistent with an underlying biological pressure that does not relent.
• The persistence of these adaptations is part of why major medical organisations have reframed obesity as a chronic disease requiring ongoing management.
• STEP and SURMOUNT trial data show sustained appetite suppression under GLP-1 treatment, and STEP 4 demonstrated that the suppression — and the protection against regain — disappears when the medication is stopped.
• The framing of GLP-1 therapy as long-term or indefinite reflects this evidence: the hormonal environment the medication produces is the environment in which the new weight is sustainable.